Is Pacific Biosciences (PACB) The Best Rising Penny Stock?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) has gained more than 12% over the past month and roughly 35% since the global launch of SPRQ-Nx sequencing chemistry. Wall Street expects more than 59% upside from the current level, making it one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) on May 26 launched SPRQ-Nx, a new sequencing chemistry for its Revio HiFi platform. Management noted that one of the key benefits of the new sequencing chemistry is cost, as genome sequencing drops to a list price of $345, with the potential to go below $300 at scale. This reflects a 30% reduction from the previous chemistry.

​Moreover, management also highlighted a key innovation, which is a reusable SMRT Cell consumable, suggesting that the same physical component can be used multiple times, directly cutting costs. Notably, beta testing across more than 1,400 runs at 20 sites worldwide showed higher yields and lower failure rates compared to the prior version.

The company also upgraded its AI-powered accuracy tool, DeepConsensus. The tool has been developed in partnership with Google, and the updates enabled by Google’s AlphaEvolve coding agent improve both speed and data quality. The company also plans to bring the chemistry to its smaller Vega benchtop system later in 2026.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a firm that develops, manufactures, and markets advanced sequencing solutions for genetic analysis. It operates through America, Europe, the Middle East, and Africa, and Asia Pacific segments.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.